Show more...Show more...Show more...
Record Information
Version2.0
Created at2022-05-11 16:37:25 UTC
Updated at2022-05-11 16:37:25 UTC
NP-MRD IDNP0087015
Secondary Accession NumbersNone
Natural Product Identification
Common Name6-Keto-prostaglandin F1a
Description6-Keto-prostaglandin F1a, also known as 6-keto-PGF1a or 6-oxo-PGF1alpha, belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. Thus, 6-keto-prostaglandin F1A is considered to be an eicosanoid lipid molecule. 6-Keto-prostaglandin F1a is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. 6-Keto-prostaglandin F1a was first documented in 1983 (PMID: 6589104). In humans, 6-keto-prostaglandin F1A is involved in mefenamic acid action pathway (PMID: 11871383) (PMID: 9223652) (PMID: 12959636) (PMID: 9831332).
Structure
Thumb
Synonyms
Chemical FormulaC20H34O6
Average Mass370.4804 Da
Monoisotopic Mass370.23554 Da
IUPAC Name7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoic acid
Traditional Name6 keto PGF1 α
CAS Registry NumberNot Available
SMILES
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O
InChI Identifier
InChI=1S/C20H34O6/c1-2-3-4-7-14(21)10-11-16-17(19(24)13-18(16)23)12-15(22)8-5-6-9-20(25)26/h10-11,14,16-19,21,23-24H,2-9,12-13H2,1H3,(H,25,26)/b11-10+/t14-,16+,17+,18+,19-/m0/s1
InChI KeyKFGOFTHODYBSGM-ZUNNJUQCSA-N
Experimental Spectra
Not Available
Predicted Spectra
Chemical Shift Submissions
Not Available
Species
Species of Origin
Chemical Taxonomy
Description Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Long-chain fatty acid
  • Fatty alcohol
  • Hydroxy fatty acid
  • Keto fatty acid
  • Cyclopentanol
  • Cyclic alcohol
  • Secondary alcohol
  • Ketone
  • Carboxylic acid derivative
  • Carboxylic acid
  • Monocarboxylic acid or derivatives
  • Organic oxide
  • Organic oxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homomonocyclic compound
Molecular FrameworkAliphatic homomonocyclic compounds
External Descriptors
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP1.75ALOGPS
logP1.79ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)4.14ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area115.06 ŲChemAxon
Rotatable Bond Count13ChemAxon
Refractivity100 m³·mol⁻¹ChemAxon
Polarizability42.48 ųChemAxon
Number of Rings1ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDHMDB0002886
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDFDB023077
KNApSAcK IDNot Available
Chemspider ID4444411
KEGG Compound IDC05961
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN ID6782
PubChem Compound5280888
PDB IDNot Available
ChEBI ID28158
Good Scents IDNot Available
References
General References
  1. de la Cruz JP, Guerrero A, Gonzalez-Correa JA, Marquez E, Nacle I, Sanchez de la Cuesta F: Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Eur J Clin Pharmacol. 2002 Jan;57(11):775-80. doi: 10.1007/s00228-001-0391-8. [PubMed:11871383 ]
  2. Laitinen O, Seppala E, Nissila M, Vapaatalo H: Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983 Dec;2(4):401-6. doi: 10.1007/BF02041562. [PubMed:6589104 ]
  3. Jawerbaum A, Rosello Catafau J, Gonzalez ET, Novaro V, Gomez G, Gelpi E, Gimeno MA: Eicosanoid production by placental and amnion tissues from control and non-insulin-dependent diabetic rats. Influence of oxytocin in the incubating medium. Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):425-9. doi: 10.1016/s0952-3278(97)90594-9. [PubMed:9223652 ]
  4. Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet. 2003;42(12):1059-70. doi: 10.2165/00003088-200342120-00004. [PubMed:12959636 ]
  5. Katori M, Majima M, Harada Y: Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm Res. 1998 Oct;47 Suppl 2:S107-11. doi: 10.1007/s000110050293. [PubMed:9831332 ]